Education
About Us
Working with TipRanks
Follow Us
Kamada Ltd (KMDA)
:KMDA
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.74 - $9.16
Previous CloseN/A
Volume680.22K
Average Volume (3M)74.90K
Market Cap
$388.51M
Enterprise Value$169.73M
Total Cash (Recent Filing)$78.44M
Total Debt (Recent Filing)$11.06M
Price to Earnings (P/E)24.6
Beta0.64
Next Earnings
Aug 13, 2025EPS Estimate
0.09Last Dividend Ex-Date
Mar 17, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding57,505,030
10 Day Avg. Volume71,065
30 Day Avg. Volume74,904
Financial Highlights & Ratios
PEG Ratio-19.67
Price to Book (P/B)1.04
Price to Sales (P/S)0.00
P/FCF Ratio7.39
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda1.51
Forecast
1Y Price Target
$13.00Price Target Upside88.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Kamada News
PremiumCompany Announcements
Kamada Ltd’s Earnings Call Highlights Strong Growth and Expansion
PremiumCompany Announcements
Kamada Ltd. Reports Strong Q1 2025 Results
PremiumCompany Announcements
Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations
PremiumCompany Announcements
Kamada to Release Q1 2025 Financial Results on May 14
PremiumCompany Announcements
Kamada Launches Post-Marketing Research Program for CYTOGAMBulls Say, Bears Say
Bulls Say
Financial PerformanceKamada reported in-line financial results for their 1Q25, including revenues of $44.0 million, or 17% above those of 1Q24, and net income of $0.07 per share as compared to $0.04 per share in the prior year.
Product PipelineAn active internal R&D pipeline includes a novel AAT Deficiency treatment entering a Phase 3 trial, which could expand the treatment of this under-diagnosed genetic respiratory ailment.
Strategic GrowthKamada continues the growth trajectory fueled by ex US expansion and increased demand.
Bears Say
Market StrategyThe special dividend issued by the company is indicative that any potential deals are likely to be 'bite-sized' and not cause the company to deviate materially from its current strategy.
Product FocusThe stock may rally if the inhaled AAT program is discontinued, as some shareholders view it as a distraction from the company’s core competencies.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.96% Mutual Funds
3.81% Other Institutional Investors
92.89% Public Companies and Individual Investors
KMDA FAQ
What was Kamada Ltd’s price range in the past 12 months?
Kamada Ltd lowest stock price was $4.74 and its highest was $9.15 in the past 12 months.
What is Kamada Ltd’s market cap?
Kamada Ltd’s market cap is $388.51M.
When is Kamada Ltd’s upcoming earnings report date?
Kamada Ltd’s upcoming earnings report date is Aug 13, 2025 which is in 60 days.
How were Kamada Ltd’s earnings last quarter?
Kamada Ltd released its earnings results on May 14, 2025. The company reported $0.073 earnings per share for the quarter, beating the consensus estimate of $0.068 by $0.005.
Is Kamada Ltd overvalued?
According to Wall Street analysts Kamada Ltd’s price is currently Undervalued.
Does Kamada Ltd pay dividends?
Kamada Ltd pays a Notavailable dividend of $0.207 which represents an annual dividend yield of N/A. See more information on Kamada Ltd dividends here
What is Kamada Ltd’s EPS estimate?
Kamada Ltd’s EPS estimate is 0.09.
How many shares outstanding does Kamada Ltd have?
Kamada Ltd has 57,505,030 shares outstanding.
What happened to Kamada Ltd’s price movement after its last earnings report?
Kamada Ltd reported an EPS of $0.073 in its last earnings report, beating expectations of $0.068. Following the earnings report the stock price went up 2.322%.
Which hedge fund is a major shareholder of Kamada Ltd?
Among the largest hedge funds holding Kamada Ltd’s share is ARK Investment Management LLC. It holds Kamada Ltd’s shares valued at 0.
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (88.95% Upside)
$13.00 (88.95% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.29%
12-Months-Change
Fundamentals
Return on Equity
6.44%
Trailing 12-Months
Asset Growth
9.30%
Trailing 12-Months
Company Description
Kamada Ltd
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, a significant increase in adjusted EBITDA, and successful diversification of the portfolio. However, there were concerns about the flat sales of CYTOGAM and potential indirect impacts of tariffs and global trade changes. The high tax rate also raised questions, but the overall outlook remains positive with reiterated guidance and ongoing expansion efforts.Read More>KMDA Stock 12 Month Forecast
Average Price Target
$13.00
▲(88.95%Upside)